{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:29:54Z","timestamp":1790832594239,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fragile X syndrome (FXS) is a genetic disorder characterized by mutation in the FMR1 gene, leading to the absence or reduced levels of fragile X Messenger Ribonucleoprotein 1 (FMRP). This results in neurodevelopmental deficits, including autistic spectrum conditions. On the other hand, Fragile X-associated tremor\/ataxia syndrome (FXTAS) is a distinct disorder caused by the premutation in the FMR1 gene. FXTAS is associated with elevated levels of FMR1 mRNA, leading to neurodegenerative manifestations such as tremors and ataxia.<\/jats:p>\n          <jats:p>Mounting evidence suggests a link between both syndromes and mitochondrial dysfunction (MDF). In this minireview, we critically examine the intricate relationship between FXS, FXTAS, and MDF, focusing on potential therapeutic avenues to counteract or mitigate their adverse effects. Specifically, we explore the role of mitochondrial cofactors and antioxidants, with a particular emphasis on alpha-lipoic acid (ALA), carnitine (CARN) and Coenzyme Q10 (CoQ10). Findings from this review will contribute to a deeper understanding of these disorders and foster novel therapeutic strategies to enhance patient outcomes.<\/jats:p>","DOI":"10.1007\/s11033-024-09415-7","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T08:01:54Z","timestamp":1712304114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mitochondrial dysfunction in Fragile X syndrome and Fragile X-associated tremor\/ataxia syndrome: prospect use of antioxidants and mitochondrial nutrients"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6166-2620","authenticated-orcid":false,"given":"Giovanni","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-4697","authenticated-orcid":false,"given":"Alex","family":"Lyakhovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-1980","authenticated-orcid":false,"given":"Federico V.","family":"Pallard\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7519-7106","authenticated-orcid":false,"given":"Luca","family":"Tiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-3358","authenticated-orcid":false,"given":"Adriana","family":"Zatterale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-8676","authenticated-orcid":false,"given":"Marco","family":"Trifuoggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"9415_CR1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cell.2020.07.008","volume":"182","author":"P Licznerski","year":"2020","unstructured":"Licznerski P, Park HA, Rolyan H et al (2020) ATP synthase c-subunit leak causes aberrant cellular metabolism in fragile X syndrome. Cell 182:1170\u20131185. https:\/\/doi.org\/10.1016\/j.cell.2020.07.008","journal-title":"Cell"},{"key":"9415_CR2","doi-asserted-by":"publisher","first-page":"7404","DOI":"10.1096\/fj.202000283RR","volume":"34","author":"KK Griffiths","year":"2020","unstructured":"Griffiths KK, Wang A, Wang L et al (2020) Inefficient thermogenic mitochondrial respiration due to futile proton leak in a mouse model of fragile X syndrome. FASEB J 34:7404\u20137426. https:\/\/doi.org\/10.1096\/fj.202000283RR","journal-title":"FASEB J"},{"key":"9415_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbr.2008.02.015","volume":"192","author":"B Draganski","year":"2008","unstructured":"Draganski B, May A (2008) Training-induced structural changes in the adult human brain. Behav Brain Res 192:137\u2013142. https:\/\/doi.org\/10.1016\/j.bbr.2008.02.015","journal-title":"Behav Brain Res"},{"key":"9415_CR4","doi-asserted-by":"publisher","first-page":"10057","DOI":"10.1073\/pnas.0700169104","volume":"104","author":"M Zhang","year":"2007","unstructured":"Zhang M, Wang Q, Huang Y (2007) Fragile X mental retardation protein FMRP and the RNA export factor NXF2 associate with and destabilize Nxf1 mRNA in neuronal cells. Proc Natl Acad Sci U S A 104:10057\u201310062. https:\/\/doi.org\/10.1073\/pnas.0700169104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9415_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.devcel.2023.03.002","volume":"58","author":"J Geng","year":"2023","unstructured":"Geng J, Khaket TP, Pan J et al (2023) Deregulation of ER-mitochondria contact formation and mitochondrial calcium homeostasis mediated by VDAC in fragile X syndrome. Dev Cell 58:597\u2013615e10. https:\/\/doi.org\/10.1016\/j.devcel.2023.03.002","journal-title":"Dev Cell"},{"key":"9415_CR6","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.3390\/ijms22168368","volume":"22","author":"LM Valor","year":"2021","unstructured":"Valor LM, Morales JC, Herv\u00e1s-Corpi\u00f3n I, Mar\u00edn R (2021) Molecular pathogenesis and peripheral monitoring of adult Fragile X-associated syndromes. Int J Mol Sci 22:8368. https:\/\/doi.org\/10.3390\/ijms22168368","journal-title":"Int J Mol Sci"},{"key":"9415_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1042\/BJ20091960","volume":"429","author":"C Ross-Inta","year":"2010","unstructured":"Ross-Inta C, Omanska-Klusek A, Wong S et al (2010) Evidence of mitochondrial dysfunction in fragile X-associated tremor\/ataxia syndrome. Biochem J 429:545\u2013552. https:\/\/doi.org\/10.1042\/BJ20091960","journal-title":"Biochem J"},{"key":"9415_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12311-016-0779-8","volume":"15","author":"E Napoli","year":"2016","unstructured":"Napoli E, Song G, Wong S et al (2016) Altered bioenergetics in primary dermal fibroblasts from adult carriers of the FMR1 premutation before the onset of the neurodegenerative disease Fragile X-Associated Tremor\/Ataxia Syndrome. Cerebellum 15:552\u2013564. https:\/\/doi.org\/10.1007\/s12311-016-0779-8","journal-title":"Cerebellum"},{"key":"9415_CR9","doi-asserted-by":"publisher","first-page":"8548910","DOI":"10.1155\/2016\/8548910","volume":"2016","author":"E Lima-Cabello","year":"2016","unstructured":"Lima-Cabello E, Garcia-Guirado F, Calvo-Medina R et al (2016) An abnormal nitric oxide metabolism contributes to brain oxidative stress in the mouse model for the Fragile X Syndrome, a possible role in intellectual disability. Oxid Med Cell Longev 2016:8548910. https:\/\/doi.org\/10.1155\/2016\/8548910","journal-title":"Oxid Med Cell Longev"},{"key":"9415_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fgene.2018.00338","volume":"9","author":"E Napoli","year":"2018","unstructured":"Napoli E, Schneider A, Hagerman R et al (2018) Impact of FMR1 premutation on neurobehavior and bioenergetics in young monozygotic twins. Front Genet 9:338. https:\/\/doi.org\/10.3389\/fgene.2018.00338","journal-title":"Front Genet"},{"key":"9415_CR11","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1007\/s12035-016-0194-7","volume":"54","author":"MI Alvarez-Mora","year":"2017","unstructured":"Alvarez-Mora MI, Rodriguez-Revenga L, Madrigal I et al (2017) Impaired mitochondrial function and dynamics in the pathogenesis of FXTAS. Mol Neurobiol 54:6896\u20136902. https:\/\/doi.org\/10.1007\/s12035-016-0194-7","journal-title":"Mol Neurobiol"},{"key":"9415_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2119\/molmed.2016.00122","volume":"22","author":"G Song","year":"2016","unstructured":"Song G, Napoli E, Wong S et al (2016) Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor\/ataxia syndrome: use of antioxidants in precision medicine. Mol Med 22:548\u2013559. https:\/\/doi.org\/10.2119\/molmed.2016.00122","journal-title":"Mol Med"},{"key":"9415_CR13","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1007\/s12035-018-1330-3","volume":"56","author":"E Napoli","year":"2019","unstructured":"Napoli E, Schneider A, Wang JY et al (2019) Allopregnanolone treatment improves plasma metabolomic profile associated with GABA metabolism in Fragile X-Associated Tremor\/Ataxia syndrome: a pilot study. Mol Neurobiol 56:3702\u20133713. https:\/\/doi.org\/10.1007\/s12035-018-1330-3","journal-title":"Mol Neurobiol"},{"key":"9415_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neubiorev.2014.01.012","volume":"46","author":"D Valenti","year":"2014","unstructured":"Valenti D, de Bar L, De Filippis B et al (2014) Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev 46:202\u2013217. https:\/\/doi.org\/10.1016\/j.neubiorev.2014.01.012","journal-title":"Neurosci Biobehav Rev"},{"key":"9415_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000446803","volume":"17","author":"DZ Loesch","year":"2017","unstructured":"Loesch DZ, Annesley SJ, Trost N et al (2017) Novel blood biomarkers are associated with white matter lesions in Fragile X- associated tremor\/ataxia syndrome. Neurodegener Dis 17:22\u201330. https:\/\/doi.org\/10.1159\/000446803","journal-title":"Neurodegener Dis"},{"key":"9415_CR16","doi-asserted-by":"publisher","first-page":"105427","DOI":"10.1016\/j.nbd.2021.105427","volume":"157","author":"E Napoli","year":"2021","unstructured":"Napoli E, Flores A, Mansuri Y et al (2021) Sulforaphane improves mitochondrial metabolism in fibroblasts from patients with fragile X-associated tremor and ataxia syndrome. Neurobiol Dis 157:105427. https:\/\/doi.org\/10.1016\/j.nbd.2021.105427","journal-title":"Neurobiol Dis"},{"key":"9415_CR17","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/ijms18061314","volume":"18","author":"J Won","year":"2017","unstructured":"Won J, Jin Y, Choi J et al (2017) Melatonin as a novel interventional candidate for fragile X syndrome with autism spectrum disorder in humans. Int J Mol Sci 18:1314. https:\/\/doi.org\/10.3390\/ijms18061314","journal-title":"Int J Mol Sci"},{"key":"9415_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/1096-8628(20001211)95:4<307::AID-AJMG3>3.0.CO;2-3","volume":"95","author":"EL Gould","year":"2000","unstructured":"Gould EL, Loesch DZ, Martin MJ et al (2000) Melatonin profiles and sleep characteristics in boys with fragile X syndrome: a preliminary study. Am J Med Genet 95:307\u2013315 PMID: 11186882","journal-title":"Am J Med Genet"},{"key":"9415_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5664\/jcsm.27443","volume":"5","author":"J Wirojanan","year":"2009","unstructured":"Wirojanan J, Jacquemont S, Diaz R et al (2009) The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 5:145\u2013150 PMID: 19968048","journal-title":"J Clin Sleep Med"},{"key":"9415_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/npp.2008.152","volume":"34","author":"Y de Diego-Otero","year":"2009","unstructured":"de Diego-Otero Y, Romero-Zerbo Y, el Bekay R et al (2009) Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 34:1011\u20131026. https:\/\/doi.org\/10.1038\/npp.2008.152","journal-title":"Neuropsychopharmacology"},{"key":"9415_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/1745-6215-15-345","volume":"15","author":"Y de Diego-Otero","year":"2014","unstructured":"de Diego-Otero Y, Calvo-Medina R, Quintero-Navarro C et al (2014) A combination of ascorbic acid and \u03b1-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial. Trials 15:345. https:\/\/doi.org\/10.1186\/1745-6215-15-345","journal-title":"Trials"},{"key":"9415_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clnu.2019.02.028","volume":"39","author":"R de la Torre","year":"2020","unstructured":"de la Torre R, de Sola S, Farr\u00e9 M et al (2020) A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with fragile X syndrome. Clin Nutr 39:378\u2013387. https:\/\/doi.org\/10.1016\/j.clnu.2019.02.028","journal-title":"Clin Nutr"},{"key":"9415_CR23","doi-asserted-by":"publisher","first-page":"105036","DOI":"10.1016\/j.neuint.2021.105036","volume":"146","author":"GG Vandenberg","year":"2021","unstructured":"Vandenberg GG, Dawson NJ, Head A et al (2021) Astrocyte-mediated disruption of ROS homeostasis in Fragile X mouse model. Neurochem Int 146:105036. https:\/\/doi.org\/10.1016\/j.neuint.2021.105036","journal-title":"Neurochem Int"},{"key":"9415_CR24","doi-asserted-by":"publisher","first-page":"C125","DOI":"10.1152\/ajpcell.00130.2021","volume":"322","author":"GG Vandenberg","year":"2022","unstructured":"Vandenberg GG, Thotakura A, Scott AL (2022) Mitochondrial bioenergetics of astrocytes in Fragile X syndrome: new perspectives on culture conditions and sex effect. Am J Physiol Cell Physiol 322:C125\u2013C135. https:\/\/doi.org\/10.1152\/ajpcell.00130.2021","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"9415_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/hmg\/ddr437","volume":"21","author":"H Tan","year":"2012","unstructured":"Tan H, Qurashi A, Poidevin M et al (2012) Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration. Hum Mol Genet 21(1):57\u201365. https:\/\/doi.org\/10.1093\/hmg\/ddr437","journal-title":"Hum Mol Genet"},{"key":"9415_CR26","doi-asserted-by":"publisher","first-page":"e1002102","DOI":"10.1371\/journal.pgen.1002102","volume":"7","author":"A Qurashi","year":"2011","unstructured":"Qurashi A, Li W, Zhou JY et al (2011) Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by Fragile X premutation rCGG repeats. PLoS Genet 7:e1002102. https:\/\/doi.org\/10.1371\/journal.pgen.1002102","journal-title":"PLoS Genet"},{"key":"9415_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.parkreldis.2008.04.037","volume":"15","author":"DA Hall","year":"2009","unstructured":"Hall DA, Howard K, Hagerman R, Leehey M (2009) Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord 15:156\u2013159. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.04.037","journal-title":"Parkinsonism Relat Disord"},{"key":"9415_CR28","doi-asserted-by":"publisher","first-page":"12603","DOI":"10.3390\/ijms232012603","volume":"23","author":"D Mantle","year":"2022","unstructured":"Mantle D, Hargreaves IP (2022) Mitochondrial dysfunction and neurodegenerative disorders: role of nutritional supplementation. Int J Mol Sci 23:12603. https:\/\/doi.org\/10.3390\/ijms232012603","journal-title":"Int J Mol Sci"},{"key":"9415_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2377-9-53","volume":"9","author":"JR Rueda","year":"2009","unstructured":"Rueda JR, Ballesteros J, Tejada MI (2009) Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol 9:53. https:\/\/doi.org\/10.1186\/1471-2377-9-53","journal-title":"BMC Neurol"},{"key":"9415_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/PGPM.S338846","volume":"14","author":"DK Sodhi","year":"2021","unstructured":"Sodhi DK, Hagerman R (2021) Fragile X premutation: medications, therapy and lifestyle advice. Pharmgenomics Pers Med 14:1689\u20131699. https:\/\/doi.org\/10.2147\/PGPM.S338846","journal-title":"Pharmgenomics Pers Med"},{"key":"9415_CR31","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1111\/j.1460-9568.2007.05939.x","volume":"26","author":"R el Bekay","year":"2007","unstructured":"el Bekay R, Romero-Zerbo Y, Decara J et al (2007) Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. Eur J Neurosci 26:3169\u20133180. https:\/\/doi.org\/10.1111\/j.1460-9568.2007.05939.x","journal-title":"Eur J Neurosci"},{"key":"9415_CR32","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.7860\/JCDR\/2013\/6635.3732","volume":"7","author":"N Sivaranjani","year":"2013","unstructured":"Sivaranjani N, Rao SV, Rajeev G (2013) Role of reactive oxygen species and antioxidants in atopic dermatitis. J Clin Diagn Res 7:2683\u20132685. https:\/\/doi.org\/10.7860\/JCDR\/2013\/6635.3732","journal-title":"J Clin Diagn Res"},{"key":"9415_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ajmg.1320510428","volume":"51","author":"MG Pomponi","year":"1994","unstructured":"Pomponi MG, Neri G (1994) Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am J Med Genet 51:447\u2013450. https:\/\/doi.org\/10.1002\/ajmg.1320510428","journal-title":"Am J Med Genet"},{"issue":"Suppl 1","key":"9415_CR34","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.33588\/rn.33S1.2001381","volume":"33","author":"M Calvani","year":"2001","unstructured":"Calvani M, D\u2019Iddio S, de Gaetano A et al (2001) L-acetylcarnitine treatment on fragile X patients hyperactive behaviour. Rev Neurol 33(Suppl 1):S65\u201370. https:\/\/doi.org\/10.33588\/rn.33S1.2001381","journal-title":"Rev Neurol"},{"key":"9415_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajmg.a.32268","volume":"146","author":"MG Torrioli","year":"2008","unstructured":"Torrioli MG, Vernacotola S, Peruzzi L et al (2008) A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803\u2013812. https:\/\/doi.org\/10.1002\/ajmg.a.32268","journal-title":"Am J Med Genet A"},{"key":"9415_CR36","doi-asserted-by":"publisher","first-page":"CD010012","DOI":"10.1002\/14651858.CD010012.pub2","volume":"5","author":"JR Rueda","year":"2015","unstructured":"Rueda JR, Guill\u00e9n V, Ballesteros J et al (2015) L-acetylcarnitine for treating fragile X syndrome. Cochrane Database Syst Rev 5:CD010012. https:\/\/doi.org\/10.1002\/14651858.CD010012.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"9415_CR37","doi-asserted-by":"publisher","unstructured":"Griffiths KK, Wang A, Levy RJ (2022) Assessment of open probability of the mitochondrial permeability transition pore in the setting of Coenzyme Q excess. J Vis Exp 184. https:\/\/doi.org\/10.3791\/63646","DOI":"10.3791\/63646"},{"key":"9415_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2022.04.003","volume":"65","author":"YR Somnay","year":"2022","unstructured":"Somnay YR, Wang A, Griffiths KK, Levy RJ (2022) Altered brown adipose tissue mitochondrial function in newborn fragile X syndrome mice. Mitochondrion 65:1\u201310. https:\/\/doi.org\/10.1016\/j.mito.2022.04.003","journal-title":"Mitochondrion"},{"key":"9415_CR39","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.3390\/ijms22115886","volume":"22","author":"SL Nolin","year":"2021","unstructured":"Nolin SL, Napoli E, Flores A et al (2021) Deficits in prenatal serine biosynthesis underlie the mitochondrial dysfunction associated with the autism-linked FMR1 gene. Int J Mol Sci 22:5886. https:\/\/doi.org\/10.3390\/ijms22115886","journal-title":"Int J Mol Sci"},{"key":"9415_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0891-5849(95)00017-r","volume":"19","author":"L Packer","year":"1995","unstructured":"Packer L, Witt EH, Tritschler HJ (1995) Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19:227\u2013250. https:\/\/doi.org\/10.1016\/0891-5849(95)00017-r","journal-title":"Free Radic Biol Med"},{"key":"9415_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2174\/0929867043365387","volume":"11","author":"AR Smith","year":"2004","unstructured":"Smith AR, Shenvi SV, Widlansky M et al (2004) Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 11:1135\u20131146. https:\/\/doi.org\/10.2174\/0929867043365387","journal-title":"Curr Med Chem"},{"issue":"21","key":"9415_CR42","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1042\/BCJ20160585","volume":"473","author":"C Giulivi","year":"2016","unstructured":"Giulivi C, Napoli E, Tassone F et al (2016) Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation. Biochem J 473(21):3871\u20133888. https:\/\/doi.org\/10.1042\/BCJ20160585","journal-title":"Biochem J"},{"key":"9415_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2015.11.019","volume":"371","author":"B D\u00f6rsam","year":"2016","unstructured":"D\u00f6rsam B, Fahrer J (2016) The disulfide compound \u03b1-lipoic acid and its derivatives: a novel class of anticancer agents targeting mitochondria. Cancer Lett 371:12\u201319. https:\/\/doi.org\/10.1016\/j.canlet.2015.11.019","journal-title":"Cancer Lett"},{"key":"9415_CR44","doi-asserted-by":"publisher","first-page":"10393","DOI":"10.3390\/ijms221910393","volume":"22","author":"PR Fisher","year":"2021","unstructured":"Fisher PR, Allan CY, Sanislav O et al (2021) Relationships between mitochondrial function, AMPK, and TORC1 signaling in lymphoblasts with premutation alleles of the FMR1 gene. Int J Mol Sci 22:10393. https:\/\/doi.org\/10.3390\/ijms221910393","journal-title":"Int J Mol Sci"},{"key":"9415_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00439-019-02104-7","volume":"139","author":"V Nobile","year":"2020","unstructured":"Nobile V, Palumbo F, Lanni S et al (2020) Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene. Hum Genet 139:227\u2013245. https:\/\/doi.org\/10.1007\/s00439-019-02104-7","journal-title":"Hum Genet"},{"key":"9415_CR46","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/sj.ejhg.5201393","volume":"13","author":"E Tabolacci","year":"2005","unstructured":"Tabolacci E, Pietrobono R, Moscato U et al (2005) Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 13:641\u2013648. https:\/\/doi.org\/10.1038\/sj.ejhg.5201393","journal-title":"Eur J Hum Genet"},{"key":"9415_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/biom10050702","volume":"10","author":"P La Rosa","year":"2020","unstructured":"La Rosa P, Petrillo S, Bertini ES, Piemonte F (2020) Oxidative stress in DNA repeat expansion disorders: a focus on NRF2 signaling involvement. Biomolecules 10:702. https:\/\/doi.org\/10.3390\/biom10050702","journal-title":"Biomolecules"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09415-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T20:24:52Z","timestamp":1738700692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09415-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9415"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09415-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"3 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The content of this manuscript did not require any ethics approval nor any consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declared their consent to publish the present manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"480"}}